Predicting Differences in Treatment Response and Survival Time of Lung Adenocarcinoma Patients Based on a Prognostic Risk Model of Glycolysis-Related Genes.

Zhao, Rongchang; Ding, Dan; Ding, Yan; Han, Rongbo; Wang, Xiujuan; Zhu, Chunrong

Zhao, Rongchang; Ding, Dan; Ding, Yan; Han, Rongbo; Wang, Xiujuan; Zhu, Chunrong.

Afiliación

Zhao R; Department of Oncology, Taixing People's Hospital Affiliated to Bengbu Medical College, Taixing, China.
Ding D; Department of Intensive Care Unit, Taixing People's Hospital Affiliated to Bengbu Medical College, Taixing, China.
Ding Y; Department of Oncology, Taixing People's Hospital Affiliated to Bengbu Medical College, Taixing, China.
Han R; Department of Oncology, Taixing People's Hospital Affiliated to Bengbu Medical College, Taixing, China.
Wang X; Department of Intensive Care Unit, Taixing People's Hospital Affiliated to Bengbu Medical College, Taixing, China.
Zhu C; Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China.

Front Genet ; 13: 828543, 2022.

Article en En | MEDLINE | ID: mdl-35692818

Palabras clave

drug sensitivity; glycolysis; lung adenocarcinoma; nomogram; tumor mutation burden

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Genet Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google